Chitosan-modified poly(D,L-lactide-co-glycolide) nanospheres for improving siRNA delivery and gene-silencing effects
- PMID: 20034563
- PMCID: PMC7127408
- DOI: 10.1016/j.ejpb.2009.12.007
Chitosan-modified poly(D,L-lactide-co-glycolide) nanospheres for improving siRNA delivery and gene-silencing effects
Abstract
Chitosan (CS) surface-modified poly(D,L-lactide-co-glycolide) (PLGA) nanospheres (NS) for a siRNA delivery system were evaluated in vitro. siRNA-loaded PLGA NS were prepared by an emulsion solvent diffusion (ESD) method, and the physicochemical properties of NS were investigated. The level of targeted protein expression and siRNA uptake were examined in A549 cells. CS-modified PLGA NS exhibited much higher encapsulation efficiency than unmodified PLGA NS (plain-PLGA NS). CS-modified PLGA NS showed a positive zeta potential, while plain-PLGA NS were negatively charged. siRNA uptake studies by observation with confocal laser scanning microscopy (CLSM) indicated that siRNA-loaded CS-modified PLGA NS were more effectively taken up by the cells than plain-PLGA NS. The efficiencies of different siRNA preparations were compared at the level of targeted protein expression. The gene-silencing efficiency of CS-modified PLGA NS was higher and more prolonged than those of plain-PLGA NS and naked siRNA. This result correlated with the CLSM studies, which may have been due to higher cellular uptake of CS-modified PLGA NS due to electrostatic interactions. It was concluded that CS-modified PLGA NS containing siRNA could provide an effective siRNA delivery system.
(c) 2009 Elsevier B.V. All rights reserved.
Figures






Similar articles
-
Chitosan-modified poly(D,L-lactide-co-glycolide) nanospheres for plasmid DNA delivery and HBV gene-silencing.Int J Pharm. 2011 Aug 30;415(1-2):259-66. doi: 10.1016/j.ijpharm.2011.05.053. Epub 2011 May 27. Int J Pharm. 2011. PMID: 21645597
-
Oral nuclear factor-κB decoy oligonucleotides delivery system with chitosan modified poly(D,L-lactide-co-glycolide) nanospheres for inflammatory bowel disease.Biomaterials. 2011 Jan;32(3):870-8. doi: 10.1016/j.biomaterials.2010.09.034. Biomaterials. 2011. PMID: 20934748
-
Improvements in transfection efficiency with chitosan modified poly(DL-lactide-co-glycolide) nanospheres prepared by the emulsion solvent diffusion method, for gene delivery.Chem Pharm Bull (Tokyo). 2011;59(3):298-301. doi: 10.1248/cpb.59.298. Chem Pharm Bull (Tokyo). 2011. PMID: 21372409
-
[Development of gene delivery system using PLGA nanospheres].Yakugaku Zasshi. 2007 Oct;127(10):1541-8. doi: 10.1248/yakushi.127.1541. Yakugaku Zasshi. 2007. PMID: 17917416 Review. Japanese.
-
Microencapsulation of protein drugs for drug delivery: strategy, preparation, and applications.J Control Release. 2014 Nov 10;193:324-40. doi: 10.1016/j.jconrel.2014.09.003. Epub 2014 Sep 10. J Control Release. 2014. PMID: 25218676 Review.
Cited by
-
Efficient Delivery of Transducing Polymer Nanoparticles for Gene-Mediated Induction of Osteogenesis for Bone Regeneration.Front Bioeng Biotechnol. 2020 Aug 5;8:849. doi: 10.3389/fbioe.2020.00849. eCollection 2020. Front Bioeng Biotechnol. 2020. PMID: 32850720 Free PMC article.
-
Feasibility of drug delivery to the eye's posterior segment by topical instillation of PLGA nanoparticles.Asian J Pharm Sci. 2017 Jul;12(4):394-399. doi: 10.1016/j.ajps.2017.03.002. Epub 2017 Apr 6. Asian J Pharm Sci. 2017. PMID: 32104351 Free PMC article.
-
Chitosan-Based Nanomaterial as Immune Adjuvant and Delivery Carrier for Vaccines.Vaccines (Basel). 2022 Nov 11;10(11):1906. doi: 10.3390/vaccines10111906. Vaccines (Basel). 2022. PMID: 36423002 Free PMC article. Review.
-
Non-condensing polymeric nanoparticles for targeted gene and siRNA delivery.Int J Pharm. 2012 May 1;427(1):21-34. doi: 10.1016/j.ijpharm.2011.05.036. Epub 2011 May 19. Int J Pharm. 2012. PMID: 21621597 Free PMC article. Review.
-
Aeromonas hydrophila OmpW PLGA Nanoparticle Oral Vaccine Shows a Dose-Dependent Protective Immunity in Rohu (Labeo rohita).Vaccines (Basel). 2016 Jun 1;4(2):21. doi: 10.3390/vaccines4020021. Vaccines (Basel). 2016. PMID: 27258315 Free PMC article.
References
-
- Yano J., Hirabayashi K., Nakagawa S., Yamaguchi T., Nogawa M., Kashimori I., Naito H., Kitagawa H., Ishiyama K., Ohgi T., Irimura T. Antitumor activity of small interfering RNA/cationic liposome complex in mouse models of cancer. Clin. Cancer Res. 2004;10:7721–7726. - PubMed
-
- Elbashir S.M., Harborth J., Lendeckel W., Yalcin A., Weber K., Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature. 2001;411:494–498. - PubMed
-
- Smith J., Zhang Y., Niven R. Toward development of a nonviral gene therapeutic. Adv. Drug. Deliv. Rev. 1997;26:135–150. - PubMed
-
- Büning H., Nicklin S.A., Perabo L., Hallek M., Baker A.H. AAV-based gene transfer. Curr. Opin. Mol. Ther. 2003;5:367–375. - PubMed
-
- Rudolph C., Plank C., Lausier J., Schillinger U., Müller R.H., Rosenecker J. Oligomers of the arginine-rich motif of the HIV-1 TAT protein are capable of transferring plasmid DNA into cells. J. Biol. Chem. 2003;278:11411–11418. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous